The FDA has approved collagenase clostridium histolyticum (CCH [XIAFLEX]) as the first medication to treat of Peyronie's disease (PD).
Men with hormone-sensitive metastatic prostate cancer who received docetaxel (Taxotere) given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early study results that the lead investigator called “practice changing.”
The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop there, according to recent study.
The AUA recently joined with the American Association of Clinical Urologists and the Large Urology Group Practice Association in applauding the Physician’s Caucus of the United States Senate for their “commitment to preserving patient access to independent, integrated medical services.”
Declining reimbursement remains the number one concern of practicing urologists, according to findings from the 8th installment of Urology Times' exclusive State of the Specialty survey.